Press Releases

Date Title and Summary Additional Formats
Toggle Summary Bloodworks Northwest Now Tests All Donors for COVID-19 Antibodies Looking for More Qualified Convalescent Plasma Donors
Testing Conducted Using the Highly Accurate MosaiQ COVID-19 Antibody Test from Quotient JERSEY, Channel Islands, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Bloodworks Northwest is now offering all blood donors across the Pacific Northwest free COVID-19 antibody testing with the possibility of discovering
View HTML
Toggle Summary Evaluation of the MosaiQ™ Platform Chosen as a Top Poster at the AABB 2013 Annual Meeting View HTML
Toggle Summary FDA Licenses Eight New Quotient Reagent Products for Sale in the U.S.
Products are rare antisera blood typing reagents developed and manufactured by Quotient U.S. commercialization of these products will extend the range and method of reagents available in the market for antigen phenotyping Equivalent products are already approved and commercialized outside of the
View HTML
Toggle Summary Quotient and Ortho Clinical Diagnostics Establish Exclusive Commercial Partnership for MosaiQ(TM) in the Global Patient Testing Market and Donor Testing Markets in the Developing World and Japan View HTML
Toggle Summary Quotient Announces Appointment of New Chief Financial Officer Peter Buhler and Chief Operating Officer Ed Farrell
Chris Lindop to Remain as Executive Vice President Reporting to Franz Walt CEO              JERSEY, Channel Islands , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the planned appointment of Peter Buhler as Chief Financial
View HTML
Toggle Summary Quotient Announces Appointment of Two New Board Members
JERSEY, Channel Islands, July 23, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland , today announced changes in the composition of its board of directors that will take effect later this year.  Two of
View HTML
Toggle Summary Quotient Announces Equity Awards
JERSEY, Channel Islands, July 23, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland today announced that Dr. Isabelle Buckle , Ph.D. and Dr. Catherine Larue , Ph.D.
View HTML
Toggle Summary Quotient Announces Positive Preliminary Results from the Initial Serological Disease Screening US Field Trial
JERSEY, Channel Islands , Oct. 31, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced positive preliminary US field trial data on the Initial Serological Disease Screening (SDS) Microarray. “We are very encouraged by these results.
View HTML
Toggle Summary Quotient Announces Positive Verification and Validation Results for Extended Immunohematology Microarray and Updates on Hypercare Sites and Revenue Performance in the Quarter
Successful Extended Immunohematology Verification and Validation data  paving the way for field trials Positive customer feedback and three additional hypercare sites initiated Preliminary quarterly revenue higher than guided JERSEY, Channel Islands , Oct.
View HTML
Toggle Summary Quotient Appoints Dr. Roger Dodd as Senior Scientific Advisor to the Donor Disease Screening Development Team for MosaiQ(TM) View HTML